Hormonal contraception in thrombophilic adolescents: Risk of thrombosis and recommendations

Hamostaseologie

Volumn 32, Issue 1, 2012, Pages 15-21

  Rott, H ^a  

^a Gerinnungszentrum Rhein Ruhr   (Germany)

Author keywords

Adolescents; COC; Contraception; Progestagen only pills; Thrombophilia

Indexed keywords

CHLORMADINONE ACETATE; CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; DIENOGEST PLUS ESTRADIOL VALERATE; DROSPIRENONE; ESTRADIOL VALERATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTAGEN; GESTODENE; LEVOGYNON; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MINI; NORETHISTERONE; NORETHISTERONE ENANTATE; SANAYA; SAYANA; ULIPRISTAL; UNCLASSIFIED DRUG;

ACNE VULGARIS; BLOOD CLOTTING; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG MEGADOSE; HORMONAL CONTRACEPTION; HUMAN; MENORRHAGIA; MENSTRUAL IRREGULARITY; ORAL CONTRACEPTION; PREGNANCY; PREGNANCY TERMINATION; PUERPERIUM; REVIEW; RISK ASSESSMENT; SIDE EFFECT; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ADOLESCENT; COMORBIDITY; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; GERMANY; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 84859736251     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1177     Document Type: Review

References (29)

1. German guideline "Contraception" . Deutsche Gesellschaft fur Gynakologie und Geburtshilfe. 2008. www.awmf.org/uploads/tx_szleitlinien/015-015.pdf.
2. Moerchel C, Kroeger K. Prophylaxe tiefer Bein- und Beckenvenenthrombose. Dtsch Artzeblatt 2007; 104: 2886-2893.
3. Van Vlijmen EFW, Veeger NJGM, Middeldorp S et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 2011; 118: 2055-2061.
4. Rabe T, Luxembourg B, Ludwig M et al. Contraception and thrombophilia - A statement from the German Society for Gynecological Endocrinology and Reproductive Medicine (DGGEF e.V.) and the Professional Association of German Gynaecologists. J Reproduktionsmed Endokrinol 2011; 8 (Special Issue 1): 126-167.
5. Herings RM, Urquhart J, Leufkens HG: Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127-128.
6. Kemmeren JM, Algra A, Grobbee DE: Third generation orals contraceptives and risk of venous thrombosis: metaanalysis. Br Med J 2001; 323: 131-134.
7. German S3-guideline: Prophylaxis of venous thromboembolism. 2009: www.awmf.org/uploads/tx_szleitlinien/003-001l_S3_VTE-Prophylaxe_2010.pdf
8. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception 2001; 64: 295-299.
9. Hughes Q, Watson M, Cole V et al. Upregulation of protein S by progestins. J Thromb Haemost 2007; 5: 2243-2249.
10. Royal College of Obstetricians and Gynaecologists (RCOG). Venous thromboembolism and hormonal contraception. Guideline No. 40. London: RCoG 2004; 13.
11. Van Vliet HA, Bertina RM, Dahm AE et al. Different effects of oral contraceptives containing different progestogens on protein s and tissue factor pathway inhibitor. J Thromb 2008; 6: 346-351.
12. Winkler UH. A randomized controlled doubleblind study of the effects on hemostasis to two progeston-only pills containing 75 μg desogestrel or 30 μg levonorgestrel. Contraception 1998; 57: 385-392.
13. Van Hylckama Vlieg A, Helmerhors FM, Vandenbroucke JP et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA-case control study. Br Med J 2009; 339: b2921.
14. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427-1429.
15. Meijers JCM, Middeldorp S, Tekelenburg W et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis A randomized cross-over study of two low-dose oral contraceptives. Cardiovas Res 2000; 17: 9-14.
16. Middeldorp S, Meijers JCM, van den Ende AE et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
17. WHO. Medical eligibility criteria for contraceptive use. 2008 update. http://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf
18. Sitruk-Ware R, Plu-Bureau G, Menard J et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab 2007; 92: 2074-2079.
19. Jick SS, Kaye JA, Russmann S et al. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006; 73: 223-228.
20. World Health Organization. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Contraception 1998; 57: 315-324.
21. Van Hylckama Vlieg JE, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot - Medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30: 2297-2300.
22. Meirik O, Farley TM, Sivin I, for the International Collaborative Post-marketing Surveillance of Norplant. Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization. Obstet Gynaecol 2001; 97: 539-547.
23. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354: 1610-1611.
24. Winkler UH, Howie H, Buhler K et al. A randomized controlled double-blind study of the effects on haemostasis of two progestogen-only pills containing 75 microgram desogestrel or 30 microgrammes levonorgestrel. Contraception 1998; 57: 385-392.
25. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. J Clin Endocrinol Metab 1995; 48: 1513-1547.
26. Poulter NR, Chang CL, Farley TM, Meirik O. Risk of cardiovascular diseases associated with oral progestogen preparations with therapeutic indications. Lancet 1999; 354: 1610.
27. Marik PE, Plante LA. Venous thromboembolic disease and pregnacy. N Engl J Med 2008; 359: 2025-2033.
28. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14: 1229-1239.
29. Gunterberg K, Ruge D. Hormonelle Kontrazeption und Rauchen: Aufklarung und Arzthaftung. Frauen arzt 2007; 48: 2-7.